Burgdorf – CEO Simon Michel provides an update on Ypsomed's (SIX: YPSN) first quarter of fiscal year 2026/27. Thanks to new customer projects spanning many therapeutic areas, international recognition for its innovation, and the planned expansion of manufacturing capacity, the company enjoyed a strong start to the new fiscal year.
In the first quarter of fiscal year 2026/27, Ypsomed achieved multiple strategic milestones.
Ypsomed secured 14 new customer projects, exceeding the previous year quarterly average. This success is primarily driven by four factors:
- Continued strong demand for large-volume autoinjectors such as YpsoMate 2.25 mL Pro and YpsoMate 5.5 mL.
- The growing number of biosimilar product launches.
- New indications that further diversify end markets, including infectious diseases.
- Early successes with the Clear-to-Clinic program.
International recognition for product innovation:
- YpsoLoop received the Red Dot Award for Product Design.
- YpsoMate 5.5 mL received the Drug-Device Combination Innovation Award at the CPHI China trade show.
The global capacity expansion is on track:
- In Solothurn, Ypsomed is commissioning its first high-capacity line for YpsoMate.
- In Schwerin, the company's new, fully automated high-bay warehouse has been completed.
Ypsomed will participate in the following events over the coming months and provide further insights into its strategy and business development:
- UBS Best of Switzerland Conference, Wolfsberg, 22–24 September 2026
- Ypsomed Media and Analyst Conference for the 2026/27 half year results, Virtual, 11 November 2026
- Jefferies Global Healthcare Conference, London, 17–18 November 2026
- J.P. Morgan 45th Annual Healthcare Conference, San Francisco, 11–14 January 2027
